Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients

Background:The B-cell translocation gene 2 (BTG2) is considered to act as a tumour-suppressor gene because of its antiproliferative and antimigratory activities. Higher levels of BTG2 expression in tumour cells have been linked to a better clinical outcome for several cancer entities. Here, we investigated the expression and function of BTG2 in bladder cancer.Methods:The expression of BTG2 in bladder cancer cells was silenced by RNA interference. Cell motility was investigated by wound healing and Boyden chamber assays. The protein expression of BTG2 in bladder cancer was studied by immunohistochemistry.Results:We observed that targeted suppression of BTG2 by RNA interference did not result in growth stimulation but led to a substantial inhibition of bladder cancer cell motility. Tissue microarray analyses of bladder cancer cystectomy specimens revealed that higher BTG2 expression levels within the tumours correlated strongly with a decreased cancer-specific survival for bladder cancer patients.Conclusion:These results indicate that endogenous BTG2 expression contributes to the migratory potential of bladder cancer cells. Moreover, high levels of BTG2 in bladder cancers are linked to decreased cancer-specific survival. These findings question the conception that BTG2 generally acts as a tumour suppressor and typically represents a favourable clinical marker for cancer patients.

• Publication year

  2013

• Venue

  British Journal of Cancer

• Publication date

  2013-01-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/bjc.2012.573PMID 23299537PMCID 3590653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High‐throughput SNP‐based authentication of human cell lines

  2013cited by this paper
• Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer

  2012cited by this paper
• The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro

  2012influential reference
• Current status of molecular markers for prognostication and outcome in invasive bladder cancer

  2012cited by this paper
• Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib

  2011influential reference
• Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells

  2011cited by this paper
• Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray

  2010influential reference
• Molecular pathogenesis and diagnostics of bladder cancer.

  2009cited by this paper
• Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis.

  2008cited by this paper
• B Cell Translocation Gene 2 Enhances Susceptibility of HeLa Cells to Doxorubicin-induced Oxidative Damage*

  2008cited by this paper
• In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

  2007cited by this paper
• Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling.

  2007cited by this paper
• TIS21/BTG2/PC3 as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule

  2006influential reference
• Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein.

  2006cited by this paper
• A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation.

  2006cited by this paper
• Origin of multifocal carcinomas of the bladder and upper urinary tract: Molecular analysis and clinical implications

  2005cited by this paper
• Phosphorylation of Serine 147 of tis21/BTG2/pc3 by p-Erk1/2 Induces Pin-1 Binding in Cytoplasm and Cell Death*

  2005cited by this paper
• Evasion of a Single-Step, Chemotherapy-Induced Senescence in Breast Cancer Cells: Implications for Treatment Response

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Concordance probability and discriminatory power in proportional hazards regression

  2005influential reference
• Boyden chamber assay.

  2005cited by this paper
• Urothelial tumorigenesis: a tale of divergent pathways

  2005influential reference
• BTG2, its family and its tutor.

  2004cited by this paper
• Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma

  2004cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• BTG2TIS21/PC3 induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells.

  2002cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis.

  2001cited by this paper
• In search of a function for the TIS21/PC3/BTG1/TOB family

  2001influential reference
• Arrest of G1-S Progression by the p53-Inducible Gene PC3 Is Rb Dependent and Relies on the Inhibition of Cyclin D1 Transcription

  2000cited by this paper
• Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas

  1999cited by this paper
• The use of fractional polynomials to model continuous risk variables in epidemiology.

  1999cited by this paper
• Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin‐dependent kinase 4 proteins due to overexpression of TIS21

  1998cited by this paper
• Identification of BTG2, an antiproliferative p53–dependent component of the DNA damage cellular response pathway

  1996influential reference
• Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma.

  1991cited by this paper
• A model for the computer analysis of synchronous DNA distributions obtained by flow cytometry.

  1980cited by this paper

• Anticancer agent FTY720 upregulates cell cycle regulator BTG2 via the SET/TAF-Iβ -PP2A-SMAD3 signaling pathway and induces G2/M arrest in leukemia.

  2026cites this paper
• E6AP is essential for the proliferation of HPV-positive cancer cells by preventing senescence

  2025cites this paper
• Pleiotropic Effects of Metformin on the Chemotherapy Response of HPV‐Positive Cancer Cells

  2025cites this paper
• Mast cell - tumor cell interaction related gene and microRNA expression profiles in oral squamous cell carcinoma

  2025cites this paper
• Delineating the mechanistic relevance of the TP53 gene and its mutational impact on gene expression and patients’ survival in bladder cancer

  2024influential citation
• LncRNA MIR600HG inhibits laryngeal cancer development by mediating the miR‐424‐5p/BTG2 axis

  2024cites this paper
• Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations

  2024cites this paper
• MicroRNA‐409‐3p/BTG2 signaling axis improves impaired angiogenesis and wound healing in obese mice

  2024cites this paper
• BTG2 suppresses the growth and metastasis of cervical squamous cell carcinoma.

  2023cites this paper
• Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations

  2023cites this paper
• A Review on Current and Novel Treatment Regimen on Luminal A Breast Cancer

  2023cites this paper
• Identification of Novel Diagnostic Biomarkers and Classification Patterns for Osteoarthritis by Analyzing a Specific Set of Genes Related to Inflammation

  2023cites this paper
• BTG2 and SerpinB5, a novel gene pair to evaluate the prognosis of lung adenocarcinoma

  2023cites this paper
• BTG2 Serves as a Potential Prognostic Marker and Correlates with Immune Infiltration in Lung Adenocarcinoma

  2022cites this paper
• Emerging role of antiproliferative protein BTG1 and BTG2

  2022cites this paper
• BTG2 as a tumor target for the treatment of luminal A breast cancer

  2022cites this paper
• Mir-25 Promotes Metastasis of Esophageal Cancer by Targeting BTG2

  2022cites this paper
• Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis

  2021cites this paper
• Expression and clinical significance of B cell translocation gene 2 in esophageal squamous cell carcinoma.

  2021cites this paper
• Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression

  2020cites this paper
• Unraveling the Role of microRNA and isomiRNA Networks in Multiple Primary Melanoma Pathogenesis

  2020cites this paper
• MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway

  2019cites this paper
• A fail-safe system to prevent oncogenesis by senescence is targeted by SV40 small T antigen

  2019cites this paper
• A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung cancer

  2018cites this paper
• Estradiol Prevents High Glucose-Induced β-cell Apoptosis by Decreased BTG2 Expression

  2018cites this paper
• Identification of differentially expressed genes in childhood asthma

  2018cites this paper
• Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing

  2017cites this paper
• BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells

  2017cites this paper
• Larger core size has superior technical and analytical accuracy in bladder tissue microarray

  2017cites this paper
• Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells.

  2016cites this paper
• Overexpression of BTG2 suppresses growth, migration, and invasion of human renal carcinoma cells in vitro.

  2016cites this paper
• [Structure of biobanks for urological research].

  2015cites this paper
• Signatures of accelerated somatic evolution in gene promoters in multiple cancer types

  2015cites this paper
• Struktur von Biobanken für die urologische Forschung

  2015cites this paper
• BTG2 inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/AKT pathway.

  2015cites this paper
• BTG2: a rising star of tumor suppressors (review).

  2015cites this paper
• MicroRNA-21 regulates the expression of BTG2 in HepG2 liver cancer cells

  2015cites this paper
• Control of the Normal and Pathological Development of Neural Stem and Progenitor Cells by the PC3/Tis21/Btg2 and Btg1 Genes

  2015cites this paper
• Oncogenic Human Papillomaviruses Activate the Tumor-Associated Lens Epithelial-Derived Growth Factor (LEDGF) Gene

  2014cites this paper
• Inhibition of bladder cancer invasion by Sp1‐mediated BTG2 expression via inhibition of DNA methyltransferase 1

  2014cites this paper